Phase 2
N=120
Effects of Pregabalin on Pain After Total Knee Arthroplasty
Primary Total Knee Arthroplasty
Bottom Line
View on ClinicalTrials.gov: NCT01333956 ↗Enrolled (actual)
120
Serious AEs
0.0%
Results posted
May 2016
Primary outcome: Primary: Postoperative Pain — 4; 4.8; 4.5; 4.0 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Pregabalin 50mg (Drug); Pregabalin 100mg (Drug); Pregabalin 150mg (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Hospital for Special Surgery, New York
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postoperative Pain |
4; 4.8; 4.5; 4.0; 3.6; 3.8 | — |
| SECONDARY Opioid-Related Symptom Distress Score |
.4; .4; .5; .4; .3; .3 | — |
| SECONDARY Self-assessed Sedation and Confusion |
34.5; 37.9; 55.2; 58.6; 34.5; 41.4 | — |
| SECONDARY Numeric Rating Scale (NRS) |
4.9; 5.4; 3.9; 5.7; 2.8; 2.9 | — |
| SECONDARY Neuropathic Pain |
0; 0; 0; 0 | — |
| SECONDARY Opioid Usage |
19; 18; 17; 18; 50; 46 | — |
| SECONDARY Satisfaction |
9; 8; 8; 8 | — |
Summary
Total knee arthroplasty can cause severe postoperative pain, and patients typically receive oral opioid analgesics for over 2 weeks. Side effects of pain management may impair participation in physical therapy and diminish patient satisfaction. Anecdotally, it seems that pregabalin is very helpful to patients after total knee arthroplasty. However, pregabalin can have side effects. It is not clear how much pregabalin to prescribe. Low doses may not be effective, but use of high doses may increase the incidence and severity of side effects.The purpose of this study is to determine which dosage of pregabalin is the most effective at reducing pain after knee surgery.
Eligibility Criteria
Inclusion Criteria
- Patients with osteoarthritis scheduled for primary tricompartmental total knee arthroplasty with a participating surgeon
- Age 18 to 80 years old
- Planned use of regional anesthesia
- Ability to follow study protocol
- English speaking (primary outcome obtained via telephone call and secondary outcomes include questionnaires validated in English only)
- Patients planning on being discharged home or to a rehabilitation center that has agreed to participate
Exclusion Criteria
- Patients younger than 18 years old and older than 80
- Patients intending to receive general anesthesia
- Allergy or intolerance to one of the study medications
- Patients with an ASA of IV
- Patients with hepatic (liver) failure
- Patients with chronic renal (kidney) failure (Defined as estimated creatinine clearance < 30 mL/min, based on recommendation that total daily pregabalin dose be reduced to 150 mg with Clcr < 30 mL/min, CLcr=[(140-age (years)] x weight (kg)x0.85 (for female patients)/[72xserum creatinine (mg/dL)])
- Patients with difficult to manage diabetes mellitus, including insulin-dependence
- Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
- Chronic opioid use (taking opioids for longer than 3 months)
- Patients with major prior ipsilateral open knee surgery.
- Chronic neurontin/lyrica use
Data sourced from ClinicalTrials.gov (NCT01333956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.